PDS Biotechnology Corp.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: North Brunswick NJ United States (2005)

Organization Overview

First Clinical Trial
2014
NCT02065973
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

PDS Biotechnology Corp. | PDS Biotechnology Corporation

Active Ingredients

Drugs in Phase 3 Trials (1)

Key: PDS Biotechnology Corp. (0) Acquired (1)

nimodipine (nimotop) (3 trials)

Drugs in Phase 2 Trials (2)

pds0101 (1 trial)

pembrolizumab (keytruda) (1 trial)

Drugs in Phase 1 Trials (2)

1,2-dioleoyl-3-trimethylammonium-propane chloride (1 trial)

human papillomavirus 16 monovalent (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Esophageal Squamous Cell Carcinoma (Phase 2)

Head and Neck Neoplasms (Phase 2)

Infections (Phase 1)

Papillomavirus Infections (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 5